{"id":141,"date":"2023-02-13T15:18:21","date_gmt":"2023-02-13T15:18:21","guid":{"rendered":"http:\/\/192.168.10.30\/?page_id=141"},"modified":"2023-03-15T16:55:51","modified_gmt":"2023-03-15T16:55:51","slug":"compare","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=141","title":{"rendered":"Compare"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer<\/p>\n\n\n\n

Trial summary:<\/h2>\n\n\n\n

CompARE is a phase III randomised trial comparing overall survival time and quality of life from five alternative treatments for high and intermediate risk oropharyngeal cancer. Arms 2. 3 & 4 are closed to recruitment and current randomisation is between Arm 1 (control arm) and Arm 5 (induction durvalumab followed by Arm 1 treatment).<\/p>\n\n\n\n

RT QA summary:<\/h2>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective outline and planning reviews for at least first case. Benchmark and prospective outlining for implementation of 5+5 technique.<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
Dosimetry <\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>De-ESCALaTE, NIMRAD, DARS and PATHOS<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA contact:<\/strong> compareqa.enh-tr@nhs.net<\/p>\n\n\n\n

Chief investigator:<\/strong> Prof Hisham Mehanna (University of Birmingham)<\/p>\n\n\n\n

RT Lead:<\/strong> Dr Andrew Hartley (University Hospitals Birmingham)<\/p>\n\n\n\n

Sponsor: <\/strong>University of Birmingham (compare@trials.bham.ac.uk)<\/p>\n\n\n\n

Funder:<\/strong> Clinical Trials Awards and Advisory Committee (CTAAC) and AstraZeneca<\/p>\n","protected":false},"excerpt":{"rendered":"

Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer Trial summary: CompARE is a […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-141","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=141"}],"version-history":[{"count":2,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/141\/revisions"}],"predecessor-version":[{"id":341,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/141\/revisions\/341"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}